Come and hear Orosur Mining CEO Brad George, Tekcapital CEO Clifford Gross PhD and Marshall Koval, CEO at Canadian junior miner Luminex Resources present and take live Q&A on September 6. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
No hard feelings, DonaldTrumpsWig. We move onwards and upwards.
gmcc, I don't know why you are selectively quoting my post from another thread out of context. So I ask you, why are you doing this? Why?
This is my full post in response to Be4C in the 'Who is Selling ...' thread:
"I think that for those going only by the RNS and the presentation slides on the Avacyta website there are no particular grounds for optimism. All there is is C3 finally going to start some time soon, a 3 month delay on the Phase 1a reporting and a strange thing called FAPi PET imaging data. And Phase 2 starting in H2 next year (so may or may not happen anytime after H1 really). Would that make you optimistic?"
Now please explain what issue you have with that and why you have decided to quote extracts out of context...
I used to respect you for your postings here but now... well you just seem inexplicably vindictive (not that that bothers me, I just don't like liars).
Lol at T10 Timster
My comments were not aimed at you personally and I'm sorry if you viewed it that way. They were aimed at the regular 'bashers' who appear daily and use the LFT and the lack of share purchases to unsettle novice investors.
I will however pick you up on some of your research, particularly the bit about me being a 'rookie' and a 'newbie'. I've been invested since 2019 and a quick check will show I've been posting on here since 2020, I might also add that my shaving mirror reminds me every morning that I am almost certainly one of the 'seniors'
Oh and if you don't like offensive language then holding PL, Timster and Rorke's up as paragons of virtue is probably a mistake (I'm sure their **** count is way ahead of mine)
Having said that, like you, I am grateful for the excellent contributions we've received in recent days and as a heavily invested LTH I'm incredibly excited at both the financial and holistic benefits AVCT will bring to us all.
Mr A your words " there are no particular grounds for optimism." really !
----pre|CISION™ technology springs to mind just for starters .
DonaldTrumpsWig - I shouldn't bite but I will in view of your offensive tone.
"Any PI that doesn't understand that is either a moron or so under researched they really shouldn't be investing their hard earned here."
I suggest that you go back and read the thread properly (at all?) and, secondly, show a little respect to your seniors, those of us who WERE here and highly active on this board long before you - the pioneers at the start of the LFT project, unlike yourself - a mere rookie who falls into the shade when held-up against the likes of myself, PL75, Timster, Rorke's Drift, SeeThreeIPOand and various others. I'll also point out that it's "rose tinted" and offensive individuals such as yourself who bring about negative ructions across the board through calling others "morons" just because they may happen to raise contrarian views to your own. You will also benefit from a look at RAH00084's very positive input to the thread, by way of an example of how to conduct yourself in a "discussion", even when disagreeing. The posters I've named above - the early settlers here - would all be highly unlikely to disagree with any of the observations made in this thread but that is clearly because they ARE secure in their investment and do not feel the need to be overly defensive So, for your benefit as a relative newbie to us elite members, I'll explain how it was agreed throughout the thread that AS - who we think just might go ever so slightly beyond "zero reference" between Therapeutics and Diagnostics - now has an opportunity to avoid the same communication mistakes that he made before your arrival in those very early days.
gmcc, my point in that partial quote - from another thread - was about what the company has put in the public domain and how people are unlikely to be optimistic about the company given those bald facts with no explanations.
the T10 can't be reasoned with. It doesn't feel pity, or remorse, or fear. And it absolutely will not stop... ever, until you are dead!
Or until the SP is £200 ex chi-nah
Malfunction: The Hurst10 bot has a coding error - incorrectly spelling 'Too' as 'To' - needs to be taken off-line (permanently).
With ref to lack of directors buying, perhaps they are in closed period?
ie. To much sensitive news being released shortly?
Mr A "a 3 month delay on the Phase 1a " :
That Avacta have commenced a first in human phase one trial is a tremendous achievement for the company in its own right .
This is not Amazon Prime order today get delivery tomorrow so very good reasons why most clinical trials give start /end dates in years .Delays do and will occur on most clinical trials . Just browse through the register .
We are indeed fortunate Avacta have issued informative guidelines for phase1a and Phase1b but apparently for some here "damned if you do and damned if you don't"
Guess easy to play at being armchair CEO.
AVA6000 clinical record states
"Estimated Primary Completion Date :May 31, 2023
Estimated Study Completion Date : June 30, 2023"
'SP not reflecting what can be inferred from some very informed private investors. I think this is because investor sentiment 'bruised' from LFT fiasco'
That statement is somewhat of an oxymoron, very informed PI's are not bruised from the LFT fiasco because they know the current opportunity has zero reference to the LFT beyond the funds it provided via the raise.
Any PI that doesn't understand that is either a moron or so under researched they really shouldn't be investing their hard earned here.
On the subject of the ongoing pathetic bashing attempts based on the lack of Director share purchases, again, research would tell the morons via the RNS of the 28th April an additional 2,000,000 shares were made available via EMI & LTIP schemes to ADD to 'the outstanding options ALREADY issued'
Same HG. I increased my holding by 10% off the back of the latest excellent update.
Anyone notice how C1 started 10 months ago, C2 4 months ago & C3 is on target to be complete in 2 (ish) months.
C1 unlocked the platform. The ‘full package’, PK & biopsies, seals any deal.
Having attended the AGM, met AS and a few related parties, listened to his presentation and Q & A, I came away, seriously impressed with Dr Smith's capabilities as a scientist and as a CEO. That is why I have since increased my position in Avacta.
DE2 announcement in early July would mean that DE1 had taken 5 months. Could DE2 be completed and the data analysed and presented by the end of Q3? It would be good if it could be, but we must be prepared for the data being released during Q4 and into late Q4 or even Q1/2023 if there is DE3.
"Especially with Avacta's expectation of DE2 for C3 and 2x US sites to come online & contribute to P1A. To keep on track, I would be expecting both of these RNS's in July."
I agree that both of these in July will enhance the sp!
What I find interesting is that AS is already predicting/second guessing DE2 even though the SDMC is independent! He must be closely informed even though not in an executive/deciding role! I think he said DE2 will be "very shortly". I know AS timescales are maybe a bit arbitrary, but I also take that to be ca mid July, like you!
Ditto stick to the RNS info not the directors fireside chats with a random you tube Finance channel, I tend to caveat a lot of what is said outside the RNS’s with most CEO’s - from painful £experience
Last weeks headlines within the RNS
‘Up to six clinical trial sites in UK:
• Active sites: St James’ Leeds, The Royal Marsden,
London and The Christie, Manchester.
• The Beatson, Glasgow and the Freeman, Newcastle now open and screening patients.
• Starting dose with cohort 1 was 80 mg/m2 AVA6000 (which is equivalent to 54 mg/m2 of Doxorubicin).
• First patient dosed on 11th August 2021 at The Royal Marsden.
• Dose escalated February 2022 to 120 mg/m2 and second cohort progressing well.
• US IND approved by FDA in November 2021:
• Two US clinical trial sites being initiated and should contribute to the dose escalation phase’
The above good enough for me at this stage
Its a fair point, RAH, but in the interests of balance, you could argue that it was our partners (Cytiva et al) who were developing the LFT whilst AS was the public face for communication purposes. My real point here is that AVA6000 also gives AS a very real chance to regain his credibility on the company communications front.
I think yours is a very fair point, valueinv, in as much as, for me, there was always a "Boris element" (the ramping aspect) to AS's character during the height of the LFT development through his presentations. There will inevitably be a hangover from that on his credibility front for some of us. I do ask myself (and you cannot blame anyone who was around at that time for doing so), is he one of those people who always feels a need to be overly positive and finds it very hard to admit setbacks? I do think though, as has been previously stated, the LFT development placed him out of his depth although - whether through luck or judgement - it did enable the fundraise. You wouldn't expect Abingdon to know too much about Affimers in short order. AS's area of expertise is what has brought us to where we are now with this trial. Things are looking good on that front but for the sake of AS's future credibility, thus removing any doubts, this needs to be a success through key, prompt, honest and transparent updates being given throughout (where required).
'SP not reflecting what can be inferred'
Which is superb for those that believe Avacta could be on the cusp of disrupting a (sadly) growing $60B market. More time to load up ahead of the 'big, big inflection point'. End of September will come around very quickly. Especially with Avacta's expectation of DE2 for C3 and 2x US sites to come online & contribute to P1A. To keep on track, I would be expecting both of these RNS's in July.
SP not reflecting what can be inferred from some very informed private investors. I think this is because investor sentiment 'bruised' from LFT fiasco, despite the super confident CEO at the time and current biotech mkt sentiment. I guess the former enabled the company to raise significant cash at the time, which is proving very useful for the therapeutic bit. Without that large cash raise, Avacta would have been forced to prematurely sell future royalty or carry out significant dilution. Lets hope therapeutic 'leg' now delivers!